Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: Progress and emerging issues in research and policy

  • University of California la Jolla
  • University of California
  • University of California Los Angeles
  • World Health Organization
  • Johns Hopkins Bloomberg School of Public Health

Producción científica: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

40 Citas (Scopus)

Resumen

Background: In this article, we present recent evidence from studies focused on the implementation, effectiveness and costeffectiveness of pre-exposure prophylaxis (PrEP) for HIV infection; discuss PrEP scale-up to date, including the observed levels of access and policy development; and elaborate on key emerging policy and research issues to consider for further scale-up, with a special focus on lower-middle income countries. Discussion: The 2015 WHO Early Release Guidelines for HIV Treatment and Prevention reflect both scientific evidence and new policy perspectives. Those guidelines present a timely challenge to health systems for the scaling up of not only treatment for every person living with HIV infection but also the offer of PrEP to those at substantial risk. Delivery and uptake of both universal antiretroviral therapy (ART) and PrEP will require nation-wide commitment and could reinvigorate health systems to develop more comprehensive "combination prevention" programmes and support wider testing linked to both treatments and other prevention options for populations at highest risk who are currently not accessing services. Various gaps in current health systems will need to be addressed to achieve strategic scale-up of PrEP, including developing prioritization strategies, strengthening drug regulations, determining cost and funding sources, training health providers, supporting user adherence and creating demand. Conclusions: The initial steps in the scale-up of PrEP globally suggest feasibility, acceptability and likely impact. However, to prevent setbacks in less well-resourced settings, countries will need to anticipate and address challenges such as operational and health systems barriers, drug cost and regulatory policies, health providers' openness to prescribing PrEP to populations at substantial risk, demand and legal and human rights issues. Emerging problems will require creative solutions and will continue to illustrate the complexity of PrEP implementation.

Idioma originalInglés
Número de artículo21108
PublicaciónJournal of the International AIDS Society
Volumen19
DOI
EstadoPublicada - 18 oct. 2016

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

  1. ODS 3: Salud y bienestar
    ODS 3: Salud y bienestar
  2. ODS 5: Igualdad de género
    ODS 5: Igualdad de género
  3. ODS 16: Paz, justicia e instituciones sólidas
    ODS 16: Paz, justicia e instituciones sólidas
  4. ODS 17: Alianzas para lograr los objetivos
    ODS 17: Alianzas para lograr los objetivos

Huella

Profundice en los temas de investigación de 'Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: Progress and emerging issues in research and policy'. En conjunto forman una huella única.

Citar esto